Ribociclib Plus Endocrine Therapy Increases Overall Survival in Premenopausal Breast Cancer

Premenopausal women who are diagnosed with breast cancer usually have a worse prognosis than those diagnosed who are postmenopausal; however, they receive similar therapy recommendations despite these prognosis differences. In order to develop a more tailored treatment for premenopausal women, researchers conducted a phase 3 trial called MONALEESA-7 (NCT02278120) that investigated ribociclib (Kisqali®, Novartis), a CDK4/6 inhibitor, in combination with endocrine therapy. Results demonstrated tha...
Continue reading

Alpelisib Now FDA Approved for Advanced Breast Cancer

The FDA has now approved alpelisib (Piqray®, Novartis) as the first PIK3CA inhibitor for postmenopausal women and men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer. Alpelisib is to be used in combination with fulvestrant following progression on or after an endocrine-based regimen. PIK3CA mutations are usually a predictor of poor prognosis, and these mutations occur in about 40% of patients with ...
Continue reading

In Premenopausal Breast Cancer, Soy Reduces Fracture Risk

According to a new study, consuming soy-containing foods and maintaining a healthy weight can help pre- and perimenopausal survivors of breast cancer to reduce their risk of fractures. Survivors of breast cancer are at a significantly increased risk of osteoporosis-related fractures, largely due to a reduction in bone mineral density caused by estrogen deprivation therapies. In addition, chemotherapy or ablation of ovarian function can induce premature menopause among younger patients with breas...
Continue reading

Oncology Nurses’ Educational Needs: CDK4/6 Inhibitors

​ Cyclin dependent kinase (CDK)4/6 inhibitors have produced tremendous advances in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer through their targeting of hormone signals that stimulate the proliferation of cancer cells. Three CDK4/6 inhibitors have been FDA approved for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer: palbociclib (Ibrance®, Pfizer Inc.), ribociclib (Kisqali®, Nova...
Continue reading

Are Cell Lines the Best Model to Analyze Breast Cancer Biology?

Cell lines—a cell culture developed in a lab from a single cell causing all cells to have the same genetic makeup—are a popular tool to analyze breast cancer biology and test drug candidates. However, sometimes a drug that shows promising preclinical performance fails when used in the clinic. To further the understanding of cell line biology compared with tumors, researchers have begun analyzing large volumes of data, called big data, consisting of genomic data from cell lines and tumors. The an...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.